CEACAM5 and neoplasm: In the present study, regorafenib plus DEB-TACE treatment achieved higher ORR and DCR compared with regorafenib monotherapy, meanwhile, regorafenib plus DEB-TACE treatment increased the negative conversion rate of tumor marker CEA compared with regorafenib monotherapy in CRLM patients who fail standard treatment regimens.